<DOC>
	<DOCNO>NCT01494324</DOCNO>
	<brief_summary>The purpose study see investigator test tissue area ablation . The investigator want know test help predict whether ablation work . The treated tumor normally evaluate CT . The CT show sign treat tumor ( ) area treat ablation . However , cancer cell may begin grow near treated area . The CT scan tell u cell new cancer cell healthy liver cell look different ablation . The test investigator study able tell u difference .</brief_summary>
	<brief_title>Examinations Tissue From Ablated Malignant Liver Metastases Predictors Outcome</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients diagnose secondary hepatic malignancy ; Patients confine liver disease stable limited extrahepatic disease ; Lesions 5cm less maximum diameter ; Patients surgical candidate refuse undergo surgery choose percutaneous ablation alternative treatment option . INR &lt; 1.5 *for patient Coumadin general clinical guideline IR ablation follow . Platelet count &gt; = 50,000 Patients &lt; 18 Less 5 mm distance tumor margin major vessel &gt; 7mm diameter ) ** Less 5 mm distance structure ( GI biliary tract ) , protect from** ablation injury technical modification hydro air dissection . INR &gt; 1.5 correct fresh frozen Plasma *for patient Coumadin general clinical guideline IR ablation follow . Platelet count &lt; 50,000 correct transfusion . Patient 3 tumor treat percutaneous ablation Patients 5 site extrahepatic disease ( include node pulmonary nodule ) **This consider exclusion IRE use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liver</keyword>
	<keyword>Thermal Ablation</keyword>
	<keyword>Dynamic CT</keyword>
	<keyword>09-122</keyword>
</DOC>